Amgen Inc.

David John Kopecky

Nobuko Nishimura

Zhihua Ma

Julie Anne Heath

Xiaoqi Chen

Xiaodong Wang

Zice Fu

Richard V Connors

Steven H Olson

Ning Chen

Frank Kayser

Jeffrey Thomas Mihalic

Julio Cesar Medina

Jonathan B Houze

Paul John Dransfield

Vatee Pattaropong

Jeffrey Deignan

Su-Jen Lai

Kevin Chao Yang

Lawrence R McGee

Xiaohui Du

Matthew R Kaller

Daniel B Horne

Alan C Cheng

Mikkel V Debenedetto

Gayathri Swaminath

Ted Charles Judd

Wen-Chen Yeh

Yinhong Chen

Aarif Yusuf Khakoo

Simon J Hedley

Patricia Lopez

Anthony B Reed

Shon Booker

Victor J Cee

Brian Alan Lanman

Robert P Farrell

Youngsook Shin

Christopher Michael Tegley

Jian Jeffrey Chen

Jennifer Rebecca Allen

Thomas T Nguyen

Longbin Liu

Nuria A Tamayo

Alexander J Pickrell

Ryan Paul Wurz

Hui-Ling Wang

John Gordon Allen

Jonathan Dante Low

James S Harvey

Dustin L McMinn

Jiasheng Fu

XianYun Jiao

Xian Yun Jiao

Daqing Sun

Qiufen May Xue

Michael J Frohn

Ana Elena Minatti

Albert Kudzovi Amegadzie

Xuelei Yan

Xiaolin Hao

Michael G Johnson

Yosup Rew

Felix Gonzalez Lopez De Turiso

Aaron C Siegmund

Vu Van Ma

Brian M Fox

Michael D Bartberger

Mario G Cardozo

John Eksterowicz

Hilary Plake Beck

Jason A Duquette

Ana Zurisadai Gonzalez Buenrostro

Christopher Neil Farthing

Darin J Gustin

Zhihong Li

Joel McIntosh

Clifford Goodman

Juan Carlos Jaen

Timothy David Cushing

Ming Yu

Derek Evan Piper

Marc Labelle

Jiwen Liu

Brian Stuart Lucas

Yingcai Wang

Lars V Heumann

Michael R Degraffenreid

Sarah Elizabeth Lively

Craig E Masse

Matthew Irvine Brown

Ryan D White

Xiaotian Zhu

Rajiv Sharma

Kevin Yang

Sarah Lively

Erin F DiMauro

John Laird Buchanan

Michael J Schmitt

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

KRAS G12C inhibitors and methods of using the same

Provided herein are methods of treating cancer with KRAS G12C inhibitors of Formula I and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers. 

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein. 

Cycloalkyl substituted triazole compounds as agonists of the APJ receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Provided herein are KRAS G12C inhibitors, compounds of formula (II), or a pharmaceutically acceptable salt thereof: compositions of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers have the following structure and are useful compounds in preparing small molecule agonists of the APJ Receptor: where the definitions of the variables are provided herein.

Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor

Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the APJ receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein.

Methods of treating heart failure

Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heterocyclic triazole compounds as agonists of the APJ receptor

Growing community of inventors

Studio City, CA, United States of America

David John Kopecky